Please login to the form below

Not currently logged in
Email:
Password:

Actavis mounts patent challenge on Velcade in US

Plans to launch own version of Takeda’s cancer drug

Takeda, Velcade

Generic drugmaker Actavis has filed a legal challenge against Takeda subsidiary Millennium Pharmaceuticals seeking to overturn its US patent protection on multiple myeloma and mantle cell lymphoma treatment Velcade.

Actavis' new parent company Watson Pharmaceuticals said the company had filed for approval of a generic product based on bortezomib, the active ingredient in Velcade, and had promptly been sued by Millennium for patent infringement.

Under US law, the lawsuit introduces an immediate 30-month stay on FDA approval of the generic unless Actavis can overturn patents protecting Velcade.

Millennium's defence of Velcade rests on two US patents (6,713,446 and 6,958,319) which were filed in 2005 and are both due to expire on January 5, 2022, according to court documents filed by the company.

Velcade is Millennium's biggest-selling product and had sales of around $740m in the 12 months ending October 31, 2012, according to IMS Health data.

The drug acts as a proteasome inhibitor and was first approved in the US in 2003 as an intravenous therapy and is now also available in a subcutaneous formulation.

Outside the US it is marketed by Johnson & Johnson, which said in November it recorded almost $1bn in sales for the product in the first nine months of 2012, a 16 per cent increase driven by approvals of the subcutaneous formulation in the EU and Canada.

2nd January 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Russian innovation at the crossroads
Despite improvements, investors face rising risks...
blog-icon_webinar_wow_c.png
E-detailing content wow factor in 2015
Many companies are reporting that the iPad novelty has worn off and healthcare professionals are demanding more than just another animation presented on a mobile device. So what exactly are...
Free White Paper: Multichannel Marketing for Pharma
Transitioning successfully to multichannel marketing takes careful planning. When done right, pharma can deliver a personalised experience for each customer. Download our white paper to learn how...